Revolution Medicines, Inc.
$43.44B- Market cap
- $45.10B
- Debt
- +$193.93M
- Cash
- −$1.85B
Capital structure 100% equity / 0% debt · EV / Revenue 3751.07x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: RVMD stock price at premium vs ARHS $210.40 current versus $0.05 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ARHS's multiple
Implied fair value · at RVMD's multiple
Snapshot Sep 8, 10:47 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVMD FY 2023 (ended Dec 31, 2023) · ARHS FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 3751.07x
Capital structure 61% equity / 39% debt · EV / Revenue 1.20x · EV / EBITDA 11.61x
RVMD carries the larger enterprise value at $43.44B against $1.66B; ARHS trades on the lower EV / Revenue multiple (1.20x vs 3751.07x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Arhaus, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.11x
1.76x
Net debt / EBITDA
Leverage against operating earnings
3.85x
3.39x
Cash and equivalents
Liquid reserves on the balance sheet
$1.85B
$253.36M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
RVMD vs AMGN
BRISTOL MYERS SQUIBB CO
RVMD vs BMY
GILEAD SCIENCES, INC.
RVMD vs GILD
INCYTE CORP
RVMD vs INCY
VERTEX PHARMACEUTICALS INC / MA
RVMD vs VRTX
Moderna, Inc.
RVMD vs MRNA
RH
RVMD vs RH
WILLIAMS SONOMA INC
RVMD vs WSM
Wayfair Inc.
RVMD vs W
LOWES COMPANIES INC
RVMD vs LOW
HOME DEPOT, INC.
RVMD vs HD
$193.93M
$736.92M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.